Source: ktsimage/Getty Images

Small-Molecule RNA-Targeting Technology Kills Cancer Cells

The RNA-editing technology, an alternative to DNA-editing tool CRISP-Cas9, potentially opens the doorway to RNA as a druggable target
Royal Philips has introduced IntelliSpace Portal 10

Philips Unveils Expanded Visualization Platform, Leads Liquid Biopsy/MRI Consortium in Winning EU Grant

Royal Philips launches next-gen IntelliSpace Portal 10 platform and leads liquid biopsy/MRI consortium in winning $7.5M from EU
Source: Haymanj

Bio-Techne Takes Minority Stake in Diagnostics Maker Astute Medical

Astute gains wider access to Bio-Techne's antibody and protein libraries, and Bio-Techne receives manufacturing rights for future products.
Source: Getty Images

NeoGenomics to Acquire Genoptix for $140M in Cash and Stock

Already strong in the hospital pathology arena, the deal will expand NeoGenomics' presence with community oncology practices
Source: LAGUNA DESIGN/Getty Images

Every Spermatogenic Cell Sequenced, Informing Infertility and Contraception

The researchers studied changes in gene expression and identified 11 cell types that could provide new insights of male infertility
Illumina said it will provide a new high-density genotyping array and its NovaSeq 6000 Sequencing Platform (pictured) to the NIH’s All of Us Research Program

Illumina Furnishes Genotyping Array, NovaSeq 6000 to NIH’s All of Us

The new array will be a high-density chip designed to enable achievement of the research program's primary genotyping-based goals
Source: Getty Images

Hitachi, ZS Genetics to Partner on “Third-Generation” Sequencing Technology Commercialization

ZS' technology employs electron microscopy for reads of 50,000 plus base pairs, reduces sampling which may lower informatics and data costs.
GNS and Swedish Cancer Institute launch collaboration aimed at advancing the use of precision medicine in care for breast cancer patients. [Source: © Arto/Fotolia.com]

Oncotype DX Prognostic Breast Cancer Test Can Lower Care Costs

Personalized treatment, guided by the Oncotype DX test, could lower the initial cost of early breast cancer care in the United States by approximately...
The U.S. Federal Trade Commission said it will approve Abbott’s $5.3 billion acquisition of Alere

Alere to Sell Blood Gas, Cardiac Marker Businesses as Abbott Deal Gains FTC Nod

The FTC will allow Abbott’s $5.3 billion acquisition of Alere, which in return will sell its blood gas and cardiac marker businesses.
Clinical OMICs Magazine: Volume 4

PerkinElmer Launches Newborn Screening Program in China

PerkinElmer entered an agreement to serve as the exclusive collaborator with China's National Health and Family Planning Commission in developing and implementing an extensive...
Scroll Up